Klaribros (Clarithromycin)

Clarithromycin is used to treat bacterial infections affecting the respiratory tract, ears, skin and gastrointestinal system.

• Community‑acquired pneumonia: eradicates the causative bacteria, improving respiratory function and reducing disease duration.
• Acute bacterial sinusitis: relieves sinus inflammation by eliminating the infecting organisms.
• Acute otitis media: clears middle‑ear infection, alleviating pain and hearing loss.
• Skin and soft‑tissue infections: combats Gram‑positive and some Gram‑negative bacteria, promoting wound healing.
• Helicobacter pylori eradication (in combination therapy): contributes to bacterial clearance, supporting ulcer healing.

• Clarithromycin binds to the 50S subunit of bacterial ribosomes, blocking the translocation step of protein synthesis. This inhibition prevents elongation of the peptide chain, halting bacterial growth. The drug exhibits a bacteriostatic effect against many Gram‑positive organisms and some Gram‑negative species, and it also possesses activity against atypical pathogens such as Mycoplasma and Chlamydia.

Clarithromycin may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Nausea: mild stomach upset often occurring after the first dose.
• Diarrhea: loose stools that may be self‑limiting.
• Abdominal pain: cramping or discomfort in the stomach area.
• Taste disturbance: altered or metallic taste.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• QT interval prolongation: may lead to cardiac arrhythmias.
• Clostridioides difficile infection: severe colitis following disruption of gut flora.

When prescribing Klaribros, clinicians should consider several safety factors.

• Renal impairment: assess kidney function and adjust dose if necessary.
• Hepatic disease: use with caution; monitor liver enzymes.
• Pregnancy: classified as Category B, generally considered safe but use only if clearly needed.
• Concomitant QT‑prolonging drugs: avoid co‑administration to reduce arrhythmia risk.
• Allergic history: discontinue if signs of hypersensitivity appear.
• Store at room temperature: keep in original container, protect from moisture and light.

Clarithromycin interacts with several medicines; some combinations should be avoided while others require monitoring.

Major Interactions (Avoid)

• Erythromycin: additive macrolide effect increases risk of QT prolongation.
• Cisapride: combined use can cause serious cardiac arrhythmias.
• Theophylline: clarithromycin inhibits metabolism, raising theophylline concentrations.

Moderate Interactions (Monitor Closely)

• Warfarin: may enhance anticoagulant effect; monitor INR.
• Statins (simvastatin, lovastatin): increased risk of myopathy; consider dose adjustment.